You are here

Europe

J&J gets Stelara okay in Europe for ulcerative colitis

J&J gets Stelara okay in Europe for ulcerative colitis

Pharmaforum

Flag link:

Roche boosts cancer approvals in Europe, pushing for a bigger slice of the I/O pie

Roche boosts cancer approvals in Europe, pushing for a bigger slice of the I/O pie

Endpoints

non-squamous cell non-small cell lung cancer

Flag link:

Keytruda combo cleared as first-line kidney cancer treatment in EU

Keytruda combo cleared as first-line kidney cancer treatment in EU

Pharmaforum

Flag link:

ESC: New Pfizer, BMS real-world data could boost Eliquis in Europe

ESC: New Pfizer, BMS real-world data could boost Eliquis in Europe

Fierce Pharma

Bristol-Myers Squibb

European Society of Cardiology

Flag link:

EMA follows FDA to approve Roche's Tecentriq combo for frontline use in triple negative breast cancer

EMA follows FDA to approve Roche's Tecentriq combo for frontline use in triple negative breast cancer

Endpoints

triple negative breast cancer

Flag link:

Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen

Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen

Endpoints

Bristol-Myers Squibb

relapsed or refractory multiple myeloma

Flag link:

Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe

Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe

Pharmaforum

Flag link:

EMA and FDA Historically Agree on Just About Every New Drug Approval, but is That Slowly Changing?

EMA and FDA Historically Agree on Just About Every New Drug Approval, but is That Slowly Changing?

RAPS.org

Flag link:

Brexit's Disruptive Impact On U.K. And European Prescription Drug Market

Brexit's Disruptive Impact On U.K. And European Prescription Drug Market

Forbes

Flag link:

Janssen gets EC approval for two new indications of Imbruvica

Janssen gets EC approval for two new indications of Imbruvica

Pharmaceutical Business Review

Waldenström’s macroglobulinemia

chronic lymphocytic leukemia

Flag link:

Novartis’ Zolgensma Joins Growing List of Medicines to Lose Accelerated Assessment Status in EU

Novartis’ Zolgensma Joins Growing List of Medicines to Lose Accelerated Assessment Status in EU

RAPS.org

Flag link:

AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib

AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib

Fierce Pharma

rheumatoid arthritis

Flag link:

European VC Firm Medicxi Closes $448 Million Fund

European VC Firm Medicxi Closes $448 Million Fund

CP Wire

venture capital

Flag link:

Here's Why Pacific Biosciences Is Tumbling Today

Here's Why Pacific Biosciences Is Tumbling Today

Motley Fool

Pacific Biosciences

Flag link:

Alexion’s Soliris follow-up Ultomiris snares EU approval

Alexion’s Soliris follow-up Ultomiris snares EU approval

Pharmaforum

Flag link:

Roche closes on EU approval for Tecentriq in breast cancer

Roche closes on EU approval for Tecentriq in breast cancer

Pharmaforum

triple negative breast cancer

Flag link:

Amgen/UCB hit another Evenity hurdle, as European regulators fail to back the osteoporosis drug

Amgen/UCB hit another Evenity hurdle, as European regulators fail to back the osteoporosis drug

Endpoints

Flag link:

'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

Endpoints

Bristol-Myers Squibb

Flag link:

AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

Yahoo/Reuters

Flag link:

Bluebird sets $1.8M price tag for blood-disease gene therapy

Bluebird sets $1.8M price tag for blood-disease gene therapy

Biopharma Dive

beta thalassemia

Flag link:

Pages